CA
CELG

Capital Advantage’s Celgene Corp CELG Stock Holding History

Capital Advantage’s Portfolio CELG Stock Details CELG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,425
Closed -$208K – 84
2017
Q3 		$208K Buy
+1,425
New +$194K 0.05% 77
2017
Q1 		– Sell
-2,225
Closed -$258K – 84
2016
Q4 		$258K Buy
+2,225
New +$248K 0.07% 67

Other funds holding CELG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Edgewood Management
Edgewood Management Greenwich, Connecticut $15.5B AUM 9.67% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Capital Advantage's CELG Position: Q4 2017 in Review

Capital Advantage sold out of Celgene Corp (CELG) in Q4 2017, closing a stake of 1,425 shares — an estimated $208K sold.

Capital Advantage first reported a position in CELG in Q4 2016 and held it in 2 quarters. The position peaked at $258K in Q4 2016. 1,470 funds tracked by Wall St. Rank hold CELG as of Q4 2017.

  • Capital Advantage reported no remaining Celgene Corp position as of Q4 2017 after selling out during the quarter.
  • Capital Advantage sold 1,425 Celgene Corp shares in Q4 2017, an estimated $208K.
  • Capital Advantage first reported a position in Celgene Corp in Q4 2016 and held it in 2 quarters.
  • Capital Advantage's Celgene Corp position peaked at $258K in Q4 2016.
  • 1,470 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2017.

Based on Capital Advantage's 13F filing for Q4 2017, filed 13 Feb 2018.